4-Chlorodiphenyl ether
Based on 1 Customer Validation
4-Chlorodiphenyl ether (4-CDE) is an estrogen-mimicking active compound. 4-Chlorodiphenyl ether maintains the survival of endometriotic cysts and exhibits estrogenic activity associated with the growth of endometriotic implants. 4-Chlorodiphenyl ether can be used in research related to endometriosis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza : 98.0%
- No. CAS: 7005-72-3
- Fòrmula: C12H9ClO
- Peso molecular:204.65
-
Almacenamiento:Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Protocolo
- Pureza y Documentación
- Referencias
-
Help & FAQs
Actividad biológica
Descripciòn
In Vivo
4-Chlorodiphenyl ether (68 nmol/kg; intravenous injection; single administration) is rapidly cleared from the blood of rays, mainly accumulates in the liver with slow elimination, and has a total body clearance rate of 4.05 mL·min−1·kg−1[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:B6C3F1 (female, adult, 22-27 g, surgically induced endometriosis)[1]
-
Dosage:10 mg/kg/day; 75 mg/kg/day; 150 mg/kg/day
-
Administration:s.c.; daily; 28 days
-
Result:Achieved 28% endometriotic cyst survival rate; showed no significant difference in cyst diameter compared to vehicle control; caused no significant alteration to hepatic BROD, MROD, EROD, or PROD enzyme activities relative to vehicle control.
Achieved 36% endometriotic cyst survival rate; showed no significant difference in cyst diameter compared to vehicle control; caused no significant alteration to hepatic BROD, MROD, EROD, or PROD enzyme activities relative to vehicle control.
Achieved 60% endometriotic cyst survival rate (significantly higher than vehicle control's 8%); showed no significant difference in cyst diameter compared to vehicle control; Significantly elevated hepatic BROD enzyme activity and significantly suppressed hepatic MROD enzyme activity relative to vehicle control, estrone-treated group, and 10/75 mg/kg/day 4-CDE groups; Resulted in hepatic EROD enzyme activity significantly lower than in the estrone-treated group; caused no significant alteration to hepatic PROD enzyme activity relative to vehicle control.
Chemical Information
-
No. CAS 7005-72-3
-
Appearance Liquid
-
Peso molecular 204.65
-
Fòrmula C12H9ClO
-
Color Light yellow to light brown
-
SMILES
ClC1=CC=C(OC=2C=CC=CC2)C=C1
-
Synonyms
4-CDE
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
Pure form -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Solvente y solubilidad
In Vitro:
DMSO : 200 mg/mL (977.28 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
In Vivo:
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 5 mg/mL (24.43 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (24.43 mM); Clear solution
This protocol yields a clear solution of ≥ 5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (50.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureza y Documentación
-
Ficha de datos (273 KB)
-
SDS (758 KB)
- English - EN (758 KB)
- Français - FR (758 KB)
- Deutsch - DE (758 KB)
- Norwegian - NO (758 KB)
- Español - ES (758 KB)
- Swedish - SV (758 KB)
- Italian - IT (758 KB)
- Korean - KR (758 KB)
- Portuguese - PT (758 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 4.8864 mL | 24.4320 mL | 48.8639 mL | 122.1598 mL |
| 5 mM | 0.9773 mL | 4.8864 mL | 9.7728 mL | 24.4320 mL | |
| 10 mM | 0.4886 mL | 2.4432 mL | 4.8864 mL | 12.2160 mL | |
| 15 mM | 0.3258 mL | 1.6288 mL | 3.2576 mL | 8.1440 mL | |
| 20 mM | 0.2443 mL | 1.2216 mL | 2.4432 mL | 6.1080 mL | |
| 25 mM | 0.1955 mL | 0.9773 mL | 1.9546 mL | 4.8864 mL | |
| 30 mM | 0.1629 mL | 0.8144 mL | 1.6288 mL | 4.0720 mL | |
| 40 mM | 0.1222 mL | 0.6108 mL | 1.2216 mL | 3.0540 mL | |
| 50 mM | 0.0977 mL | 0.4886 mL | 0.9773 mL | 2.4432 mL | |
| 60 mM | 0.0814 mL | 0.4072 mL | 0.8144 mL | 2.0360 mL | |
| 80 mM | 0.0611 mL | 0.3054 mL | 0.6108 mL | 1.5270 mL | |
| 100 mM | 0.0489 mL | 0.2443 mL | 0.4886 mL | 1.2216 mL |
4-Chlorodiphenyl ether Related Classifications
HY-76737 Related Classifications
Powered by Bioz
Keywords
- 4-Chlorodiphenyl ether
- 7005-72-3
- 4-CDE
- Estrogen Receptor/ERR
- hepatic microsomal methoxyresorufin-O-dealkylase
- hepatic microsomal benzyloxyresorufin-O-dealkylase
- B6C3F1 mice
- hepatic microsomal enzyme activity
- PROD activity
- endometriosis
- endometriotic implant growth
- cytochrome P450 isoforms
- endometriotic cysts
- winter skate
- Inhibitor
- inhibitor
- inhibit